Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

May 27, 2015

Primary Completion Date

April 9, 2026

Study Completion Date

April 9, 2026

Conditions
ALK-positive NSCLC
Interventions
DRUG

Ceritinib (LDK378)

DRUG

Nivolumab

Trial Locations (12)

3000

Novartis Investigative Site, Leuven

3084

Novartis Investigative Site, Heidelberg

19111

Fox Chase Cancer Center, Philadelphia

20133

Novartis Investigative Site, Milan

41124

Novartis Investigative Site, Modena

85259

Mayo Clinic - Arizona, Scottsdale

168583

Novartis Investigative Site, Singapore

999077

Novartis Investigative Site, Hong Kong

02114

Massachusetts General Hospital, Boston

02115

Massachusetts General Hospital Thoracic Oncolgoy, Boston

M5G 2M9

Novartis Investigative Site, Toronto

08035

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY